MPM BioImpact LLC TRVI — Trevi Therapeutics Inc

Ownership history in MPM BioImpact LLC  ·  8 quarters on record

AI Ownership Summary

MPM BioImpact LLC reported Trevi Therapeutics Inc (TRVI) in 8 quarterly 13F filings from 2024 Q1 through 2025 Q4. Peak portfolio weight reached 5.1% in 2025 Q3. The latest visible filing shows TRVI at 4.71% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this TRVI ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was MPM BioImpact LLC's position in Trevi Therapeutics Inc, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2025 Q4

TRVI was reported at 4.71% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
5.1% in 2025 Q3

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q1 to 2025 Q4

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

TRVI stock page MPM BioImpact LLC fund profile MPM BioImpact LLC full holdings
How MPM BioImpact LLC held TRVI — position size vs. price
% of Fund (quarterly)    TRVI price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 8 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2025 Q4 REDUCED — — — 3,287,087 -119,868 -3.5% 4.71% $41.2M 2026-02-14 (Est.) $10.40
2025 Q3 UNCHANGED — — — 3,406,955 — 0% 5.10% $31.2M 2025-11-14 $11.37
2025 Q2 REDUCED — — — 3,406,955 -21,411 -0.6% 3.23% $18.6M 2025-08-14 $7.49
2025 Q1 ADDED — — — 3,428,366 +333,470 +10.8% 3.71% $21.6M 2025-05-15 $6.19
2024 Q4 ADDED — — — 3,094,896 +1,556,379 +101.2% 1.81% $12.8M 2025-02-14 $4.07
2024 Q3 ADDED — — — 1,538,517 +28,343 +1.9% 0.77% $5.1M 2024-11-13 $2.86
2024 Q2 ADDED — — — 1,510,174 +169,214 +12.6% 0.70% $4.5M 2024-08-14 $2.61
2024 Q1 INITIATED — — — 1,340,960 — — 0.74% $4.6M 2024-05-15 $2.77

🏢 Other funds also holding TRVI

As of 2026 Q1 — sorted by position size

NAN FUNG TRINITY (HK) Ltd 3Y 1.5% EMERALD MUTUAL FUND ADVISERS TRUST 3Y 7Y 0.73% EMERALD ADVISERS, LLC 3Y 7Y 0.69% PFS Partners, LLC 0.43% PSP Research LLC 0.25% PEREGRINE CAPITAL MANAGEMENT LLC 3Y 7Y 0.23% FLPUTNAM INVESTMENT MANAGEMENT CO 3Y 7Y 0.19% TRUST CO OF TOLEDO NA /OH/ 3Y 7Y 0.15% Harbour Capital Advisors, LLC 3Y 7Y 0.11% CHAPIN DAVIS, INC. 3Y 0.05%

FAQ About MPM BioImpact LLC and TRVI

These are the practical questions this page is built to answer before you even open the full history table.

How long has MPM BioImpact LLC reported owning TRVI?

MPM BioImpact LLC reported TRVI across 8 quarterly 13F filings, from 2024 Q1 through 2025 Q4.

What was the largest reported TRVI position in MPM BioImpact LLC's portfolio?

The largest reported portfolio weight for TRVI was 5.10% in 2025 Q3.

What is the latest reported TRVI position on this page?

The most recent filing on this page is 2025 Q4, when MPM BioImpact LLC reported 3,287,087 shares, equal to 4.71% of portfolio, with an estimated market value of $41.2M.

What does the chart on this TRVI ownership page compare?

The chart compares MPM BioImpact LLC's quarterly TRVI portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did MPM BioImpact LLC time their TRVI position?

Based on 13F filing dates vs. subsequent TRVI price moves, MPM BioImpact LLC correctly timed 4 out of 6 reported position changes (67%). The annualised alpha on TRVI relative to SPY over the holding period was +82.0%.

← Back to MPM BioImpact LLC Holdings